文献速递血液净化与透析

提高肾脏替代治疗对大分子溶质的清除

Increasing the Removal of Large Solutes by Kidney Replacement Therapy.
PubMed 文献 · J Am Soc Nephrol · 2025-02-04

该综述讨论肾衰竭时蓄积的溶质(约40-40000 Da)的透析清除随分子量增大而下降,回顾中分子及低分子量蛋白(如β2微球蛋白)的清除策略,指出高通量透析和血液透析滤过可增加清除但受非肾脏清除与溶质分布限制,并展望延长透析及调控非肾脏清除。

要点

  • 透析对大分子溶质的清除随分子量增加而降低。
  • 高通量透析和血液透析滤过可增加大分子溶质清除。
  • 非肾脏清除与溶质分布限制血浆大分子溶质水平的降低。

核心结论

  • 增加透析对大分子溶质的清除受非肾脏清除和溶质分布限制,临床获益不能简单归因于已知大分子溶质水平降低。
  • β2微球蛋白是唯一被证实蓄积有特定不良影响的大分子溶质,识别其他大分子溶质的不良影响可能促进靶向治疗开发。

研究设计与样本

  • 综述,检索范围未明确报告,讨论肾衰竭时蓄积溶质(约40-40000 Da)的透析清除。

主要发现

  • 溶质蓄积范围约40-40000 Da,透析清除随分子量增大而降低。
  • 早期关注300-2000 Da中分子,β2微球蛋白(12000 Da)相关淀粉样变使焦点转向低分子量蛋白。
  • 高通量透析和血液透析滤过增加大分子溶质清除,但非肾脏清除和溶质分布限制血浆水平降低。
  • 高通量血液透析滤过的临床获益不能简单归因于已知大分子溶质水平降低。
  • 原始中分子范围肽类蓄积和腹膜透析对大分子溶质的清除被 largely 忽视。

临床怎么用

  • 高通量透析和血液透析滤过可用于增加大分子溶质清除。
  • 延长透析可能增加比β2微球蛋白更大溶质的清除,相关临床试验正在进行。
  • 未来可能通过调控非肾脏清除更有效降低血浆大分子溶质水平。

局限性

  • 非肾脏清除目前了解甚少。
  • 仅β2微球蛋白被证实蓄积有特定不良影响,其他大分子溶质的不良影响尚未明确。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Solutes that accumulate when the kidneys fail range in size from approximately 40 to 40,000 Da. Their dialytic clearance tends to decrease as their size increases. Disproportionate accumulation of large solutes has therefore long been considered a potential contributor to residual illness in patients on dialysis. Early efforts focused on the removal of middle molecules with mass from 300 to 2000 Da. The identification of amyloidosis caused by ß2 microglobulin ( ß2 M) with mass 12,000 Da shifted the focus to low-molecular weight proteins. High-flux dialysis and hemodiafiltration increase the clearance of these larger solutes. However, nonkidney clearance and solute compartmentalization limit the extent to which their plasma levels can be lowered by increasing their clearance during treatments of standard duration. Clinical benefits of high-volume hemodiafiltration thus cannot readily be accounted for by a reduction in the levels of known large solutes. The accumulation of peptides in the original middle molecular range and the clearance of larger solutes by peritoneal dialysis have been largely neglected. There is new interest in increasing the clearance of solutes even larger than ß2 M by extended dialysis. Ongoing clinical trials will extend our knowledge of the effects of extended dialysis and hemodiafiltration. In the future, we might more effectively reduce plasma large-solute levels by manipulating their nonkidney clearance, which is now poorly understood. ß2 M is the only large solute whose accumulation in kidney failure has been shown to have specific ill effects. Identification of the ill effects of other large solutes might prompt the development of more targeted therapies.

来源:J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Meyer TW. Increasing the Removal of Large Solutes by Kidney Replacement Therapy. J Am Soc Nephrol. 2025. PMID: 39903515. doi:10.1681/ASN.0000000651

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。